Drag a card by its title · ⚙ to size, swap or remove

The company

Lucid Diagnostics Inc.

LUCD · Nasdaq

Health CareDiagnostics & LabsNot moving yet

LUCD stood above a rising 150-day average in 8 of the last 52 weekly readings, and has been out of that trend for the last 26 weeks. It is 61.6% below that average now. Diagnostics & Labs: 50% of its 44 stocks in an uptrend (+2 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 26
Industry in uptrend: 50% +2 in 4 wk
Insider buys, 12 months: $490K
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 115 (+15)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 8 of 52 weeks.

20 Apr – 19 Oct

Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1

Sale orders, 12 months0

Buyers · sellers1 · 0

Who	Did	Shares	Traded
Dennis MatheisDirector	bought	245,000at $1.00	20 May 2026filed 21 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders115+15 on the quarter

New · exited26 · 11

Reported value$65.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
Alyeska Investment Group, L.P.new · filed 14 Aug 2026	8,856,844$9.5M	+8,856,844
BlackRock, Inc.added · filed 7 Aug 2026	8,373,117$9.0M	+3,734,874+80.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	6,556,344$7.0M	+2,401,574+57.8%
Two Seas Capital LPadded · filed 12 Aug 2026	6,000,000$6.4M	+3,000,000+100.0%
MASTERS CAPITAL MANAGEMENT LLCunchanged · filed 14 Aug 2026	4,000,000$4.3M	00.0%
Aberdeen Group plcadded · filed 31 Jul 2026	3,822,997$4.1M	+178,720+4.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	3,789,948$4.1M	+1,544,598+68.8%
STATE STREET CORPadded · filed 7 Aug 2026	2,437,337$2.6M	+882,756+56.8%
FIRST MANHATTAN CO. LLC.added · filed 14 Aug 2026	2,188,550$2.3M	+1,865,100+576.6%
WELLS FARGO & COMPANYadded · filed 14 Aug 2026	2,067,046$2.2M	+792,656+62.2%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Dennis Matheis Director · last 20 May 20268 · 0

Debra White Director · last 20 Feb 20260 · 0

Dennis M. McGrath Chief Financial Officer · last 20 Feb 20260 · 0

Jacque J. Sokolov Director · last 20 Feb 20260 · 0

James L. Cox Director · last 20 Feb 20260 · 0

John R. Palumbo Director · last 20 Feb 20260 · 0

Lishan Aklog Chief Executive Officer · last 20 Feb 20260 · 0

Michael Adam Gordon General Counsel and Secretary · last 20 Feb 20260 · 0

Ronald M. Sparks Director · last 20 Feb 20260 · 0

Shaun O'Neil President and COO · last 20 Feb 20260 · 0

Stanley Lapidus Director · last 20 Feb 20260 · 7

Pavmed Inc. 10% owner · last 15 Feb 20241 · 0

Same industry

CDNA CareDxLeading+90%

NTRA NateraLeading+47%

XGN ExagenLeading+42%

FTRE Fortrea HoldingsLeading+40%

PSNL PersonalisLeading+36%

TKNO Alpha TeknovaLeading+26%

ADPT Adaptive BiotechnologiesLeading+19%

BDSX BiodesixLeading+17%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 2025-41.7%

Free cash flow marginFY 2025 · to 31 Dec 2025-992%

Research spendFY 2025 · to 31 Dec 2025121%

Share count trendFY 2025 · to 23 Mar 202635.0%

Free cash flowFY 2025 · to 31 Dec 2025−$46.7M

Analyst forecasts

No analyst forecasts yet.